Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
(Atz) Assistant in Cardiology, Children's Hospital, and Instructor, Harvard Medical School.(Wessel) Director, Cardiac Intensive Care Unit, Children's Hospital, and Associate Professor in Pediatrics (Anesthesia), Harvard Medical School.Received from the Cardiac Intensive Care Unit, Children's Hospital, and the Departments of Cardiology, Pediatrics, and Anaesthesia, Harvard Medical School, Boston, Massachusetts. Submitted for publication March 4, 1997. Accepted for publication May 16, 1997.Address reprint requests to Dr. Atz: Cardiac ICU Office, Children's Hospital, 300 Longwood Avenue, Farley 653, Boston, Massachusetts 02115. Address electronic mail to: atz@a1.tch.harvard.edu.The acute chest syndrome (ACS), characterized by fever, chest pain, and radiographic evidence of new pulmonary infiltrate, effusion, or edema in patients with sickle cell disease is a significant cause of morbidity and death. [1] The often rapid resolution of severe ACS after exchange transfusion suggests that pulmonary vascular occlusion and ischemia and infarction play an important pathophysiologic role regardless of the etiology. [2] Recent appreciation of the importance of interactions between sickle erythrocytes and vascular endothelium has added to the understanding of the pathogenesis of vasoocclusion in sickle cell disease. [3–5] Inhaled nitric oxide has been demonstrated to selectively dilate the pulmonary circulation and to improve oxygenation when ventilation-perfusion inequalities exist. Inhaled nitric oxide may be especially useful in conditions where pulmonary vascular endothelial dysfunction is prominent. [6] We hypothesize that patients with ACS may represent a particular type of acute lung injury in which inhaled nitric oxide may improve oxygenation, cause specific pulmonary vasodilation, and potentially ameliorate the underlying vasoocclusive process.A 4.5-yr-old boy with sickle cell disease was admitted with nonspecific abdominal pain and mild desaturation. Over 48 h, he developed increasing respiratory failure and hypoxia requiring mechanical ventilation and exchange transfusion, which reduced his percent sickle hemoglobin below 30%. An echocardiogram estimated right ventricular systolic pressure of 60 mmHg. Using high frequency oscillatory ventilation (mean airway pressure, 30 cm H2O; amplitude pressure, 52 cm H2O; rate, 10 Hz; FiO2, 0.90), arterial blood gas values were pH, 7.24; PCO2, 62; PaO2, 69; saturation, 94%. Oxygen saturation in the right atrium was 70%. After obtaining written informed consent from the parents, a trial of inhaled nitric oxide was performed according to a protocol approved by the Food and Drug Administration (FDA) and the Human Investigative Committee at Children's Hospital.After 15 min of nitric oxide inhalation at 80 ppm, repeat measurements showed pH, 7.29; PCO2, 55; PaO2, 176; arterial oxygen saturation, 100%; and right atrial oxygen saturation, 81%. An echocardiogram now predicted right ventricular systolic pressure of 40 mmHg. The calculated intrapulmonary shunt fraction (Qs/Qt) decreased from 0.41 to 0.29.Nitric oxide was decreased, and the patient's ventilator settings were reduced rapidly. Successful discontinuation of nitric oxide from 5 ppm after 92 h was associated with a transient, well-tolerated decrease in PaO2from 96 to 71 mmHg. The child was converted to a volume limited mode of ventilation and extubated uneventfully 4 days later. During nitric oxide therapy, nitrogen dioxide was <or= to 2ppm, and methemoglobin remained <or= to 0.3%A 9-yr-old girl with sickle cell disease presented with a 3-day history of fever, cough, and back pain. She developed right lower and middle lobe infiltrates and right pleural effusion. A right-sided chest tube drained 300 cc of sterile serosanguinous pleural fluid. She developed increasing hypoxia with PaO2of 63 on 100% nonrebreathing mask. She was intubated, ventilated in a time-cycled, pressure-limited mode with peak inspiratory pressure of 32 cm H2O, end expiratory pressure of 10 cm H2O, rate of 14, FiO2of 0.5, and underwent exchange transfusion, which reduced the percent sickle hemoglobin below 30%. A Swan-Ganz catheter was placed, and measurements demonstrated pulmonary artery pressure, 54/31 mmHg; mean, 41 mmHg; wedge pressure, 11 mmHg; cardiac index, 5.15 l [center dot] min sup -1 [center dot] m sup -2; and calculated pulmonary vascular resistance, 5.8 U [center dot] m sup 2. She met institutional criteria for the use of inhaled nitric oxide, and parents gave written informed consent.After 15 min of nitric oxide inhalation at 80 ppm, the pulmonary artery pressure was 37/18, mean was 26 mmHg, wedge was 12 mmHg, cardiac index was 6.43 l [center dot] min sup -1 [center dot] m sup -2, and pulmonary vascular resistance was 2.2 U [center dot] m2. There was improvement in PaO2from 107 to 185 mmHg. After 47 h, nitric oxide was discontinued without clinical changes. The child subsequently weaned and was extubated 2 days later. Maximal nitrogen dio
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Cited by
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease
Aslan, M., Ryan, T. M., Adler, B., Townes, T. M., Parks, D. A., Thompson, J. A., Tousson, A., Gladwin, M. T., Patel, R. P., Tarpey, M. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221292098 · Cited by 391
Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Morris, C. R., Morris, S. M., Hagar, W., van Warmerdam, J., Claster, S., Kepka-Lenhart, D., Machado, L., Kuypers, F. A., & Vichinsky, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-967oc · Cited by 329
Evans, R. W., Armon, C., Frohman, E. M., & Goodin, D. S. (2000) · Neurology · doi:10.1212/wnl.55.7.909 · Cited by 296
McMahon, T. J., & Doctor, A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200507-066bg · Cited by 87
The Role of RIB Infarcts in the Acute Chest Syndrome of Sickle Cell Diseases
Rucknagel, D. L. (2001) · Pediatric Pathology & Molecular Medicine · doi:10.1080/15513810109168607 · Cited by 32
Metadata
- Authors
- Atz, A. M., & Wessel, D. L.
- Venue
- Anesthesiology
- Published
- 1997-10-01
- Volume
- 87
- Issue
- 4
- Pages
- 988-990
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2163204987
- Cited by
- 142
- References
- 1
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome. https://app.cochat.ai/papers/10.1097/00000542-199710000-00037
- The paper
- Atz, A. M., & Wessel, D. L. (1997). Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome. Anesthesiology. https://doi.org/10.1097/00000542-199710000-00037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.